CTLA4 and neoplasm: As the efficacy of immune checkpoint blockade is dependent on tumor-infiltrating immune cells and tumor-specific T cell responses [58], increased infiltration of TC-1/dCD80-1-induced tumors by immune cells might contribute to the sensitivity of these tumors to anti-CTLA-4 therapy.